Study #2021-0207
A phase II clinical trial to investigate ARID1A mutation and CXCL13 expression in the pre-treatment tumor samples as a combinatorial predictive biomarker for immune checkpoint therapy in metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
Nivolumab
Description
This phase II trial studies the effect of nivolumab in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) with RID1A mutation and CXCL13 expression. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab may help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Study phase:
Phase II
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-996-5012
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.